FDA Starts Talks on Another Round of Generic Drug Fees
Published Date: 6/26/2025
Notice
Summary
The FDA is gearing up to renew its Generic Drug User Fee program for 2028-2032 and wants groups like patients, doctors, and scientists to join monthly talks starting fall 2025. These fees help speed up generic drug approvals, so staying involved means smoother, faster access to affordable meds. If you want in, let the FDA know by September 4, 2025, and get ready for some important, ongoing conversations!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
GDUFA Funding May End After September 2027
The notice states that at the end of September 2027 new legislation will be required for FDA to continue collecting generic drug user fees. If new legislation is not enacted by the end of September 2027, FDA will no longer be able to collect user fees for subsequent fiscal years to fund human generic drug activities.
Opportunity to Join Monthly GDUFA Consultations
If you are a patient or consumer advocacy group, a health care professional, or a scientific or academic expert, you may notify the FDA by September 4, 2025 to join monthly consultation meetings about reauthorizing the Generic Drug User Fee program. Meetings are expected to start in the Fall of 2025 and will be held monthly, in person at the FDA White Oak campus (Silver Spring, MD) and virtually using Microsoft Teams.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11768, Intertek Testing Services NA, Inc.: Grant of Expansion of Recognition
OSHA just gave Intertek Testing Services NA, Inc. the green light to test and certify two new types of products starting June 26, 2025. This means companies using Intertek can trust their products meet safety standards faster and easier. If you rely on product safety testing, this expansion could speed things up without extra costs.
Next: 2025-11770, Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of new filings from power companies about rate changes, complaints, and approvals. These updates could affect electricity prices and operations starting as soon as May 2025 and as late as early 2026. If you’re involved with these companies or follow energy rates, keep an eye out for public comments due in early July!